FDA Advisory Panel Backs Bayer Drug for Lung Disease

FDA Advisory Panel Backs Bayer Drug for Lung Disease

The product was reviewed on Tuesday by FDA's cardiovascular and renal drugs advisory committee, which is made up of non-FDA medical experts. The panel voted 11-0 in the affirmative on a question that asked whether riociguat should be approved for the 

7
Like
Save

Comments

Write a comment

*